Skip to content

Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder

Artificial Intelligence on Molecular Imaging to Predict the Risks of Parkinson's Disease for Patients With Rapid Eye Movement Sleep Behavior Disorder

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06629207
Acronym
NUK-RBD
Enrollment
20
Registered
2024-10-08
Start date
2024-10-07
Completion date
2026-08-01
Last updated
2024-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia, Lewy Body, Parkinson Disease, REM Sleep Behavior Disorder

Keywords

Parkinson Disease, Artificial Intelligence, REM Sleep Behavior Disorder

Brief summary

The study aims to systematically document the course of REM sleep behavior disorder (RBD) and investigate possible clinical and imaging biomarkers for disease progression and conversion risk to Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). The study will use artificial intelligence to analyze imaging and develop a reliable method to predict and stratify patients approaching conversion to overt a-synucleinopathy. Participants will be clinically evaluated and 2 imaging procedures will be done.

Interventions

FDG-PET scans will be acquired in a Siemens Biograph Vision Quadra PET/CT (Siemens, Germany) at 30-minute post-injection of approximately 80 MBq 18F-FDG. The duration of the acquisition is 20 minutes. The PET images will be reconstructed with the vendor's time of flight (TOF) point-spread-function (PSF) algorithm, following corrections for randoms, scatter, and decay. Attenuation correction will be performed first using low-dose CT.

DEVICESPECT : 123 I-FP-CIT (DATSCAN)

DaT-Scans will be acquired in a GE Discovery NM/CT 670 Pro™. After injection of approximately 110 MBq 123I-FP-CIT, images will be acquired within 4 h post-injection. The duration of the acquisition is 35 minutes.

DEVICEMRI

MRI examination to exclude structural brain anomalies.

Sponsors

Insel Gruppe AG, University Hospital Bern
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Confirmed clinical iRBD diagnosis by movement disorder specialists according to the International Classification of Sleep Disorders 2. Written informed consent

Exclusion criteria

1. Known diagnosis of PD or other neurodegenerative disorder 2. Unequivocal signs of parkinsonism on examination 3. Narcolepsy or other known causes of RBD 4. Moderate to severe obstructive sleep apnea 5. Abnormal neurological or MRI examination

Design outcomes

Primary

MeasureTime frameDescription
Assessment of Deep Learning Model Accuracy in Predicting Neurodegenerative Conversion in isolated REM sleep behavior disorder (iRBD) through Early Biomarker DetectionFrom enrollment to end of follow-up period, expected to be 48 monthsThe investigators aim to evaluate the predictive accuracy of a deep learning model in identifying patients with iRBD who will progress to a neurodegenerative disorder. The primary outcome will assess the model's sensitivity in detecting early imaging biomarkers linked to disease progression, with the goal of enabling earlier intervention and improving long-term outcomes.

Secondary

MeasureTime frameDescription
Comparison of the Estimated versus Observed Annual Conversion Risk of Isolated Rapid Eye Movement Behavior Disorder (iRBD) to Neurodegenerative DisordersFrom enrollment to end of follow-up period, expected to be 48 monthsThe investigators aim to compare the estimated annual conversion risk of 6.3% in patients with iRBD to Parkinson's disease or another overt alpha-synucleinopathy with the conversion rates observed in the study.
Evaluation of Deep Learning Model Accuracy in Predicting Conversion of Isolated REM Sleep Behavior Disorder (iRBD) to Parkinson's DiseaseFrom enrollment to end of follow-up period, expected to be 48 monthsThe investigators aim to evaluate the accuracy, receiver operating characteristic curves and area under the curve, specificity, and positive and negative predictive values of the applied deep learning method, predicting the conversion risk from iRBD to Parkinson's disease or another overt alpha-synucleinopathy.

Countries

Switzerland

Contacts

Primary ContactAxel Rominger, Prof. Dr. med.
axel.rominger@insel.ch+41 316322610
Backup ContactFranziska Strunz, PhD
studies.nuk@insel.ch+41 316643022

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026